First week on Ozempic: what the science says about early results

What did @queen_tempest actually say?

She reported a smooth first week on semaglutide (she calls it "ozemphic") with zero side effects and clear appetite suppression. Her words: "I haven't had any symptoms and these side effects or anything like that" and "it has definitely curd my appetite." She's eating less frequently, going from breakfast around 9 a.m. to not feeling hungry again until early afternoon. She also counts Uber delivery work as her primary movement and is considering adding treadmill walks.

That's the full picture she's painting: early win, no complaints, optimism about what's ahead. She's not making medical claims or telling anyone to take a specific dose. She's sharing a personal experience, which is worth keeping in mind as we dig into whether that experience is typical or unusually rosy.

Does the science back this up?

Partially. The appetite suppression she describes is real and well-documented. The zero-side-effects story is where things get statistically unlikely, though not impossible.

Semaglutide works by mimicking GLP-1, a gut hormone that slows gastric emptying and signals satiety to the brain. The appetite reduction she's noticing, eating less often and feeling full longer, is exactly the mechanism researchers expected. A 2021 trial by Wilding et al. in the New England Journal of Medicine found that 68-week semaglutide treatment produced significant reductions in energy intake and appetite scores compared to placebo.

On the side effects question: the SUSTAIN and STEP trial data consistently show that nausea affects roughly 44 percent of semaglutide users, vomiting around 24 percent, and diarrhea about 30 percent, particularly in the early titration phase. A 2022 review by Davies et al. in Diabetes Care confirmed that GI adverse events peak during the dose-escalation period. One week in, at what is typically a low starting dose, milder or absent symptoms are more common than later, so her experience isn't impossible. It's just not the norm.

What did they get wrong (or right)?

She got the appetite effect right. The "no side effects" framing is where she risks misleading her audience, not because she's lying, but because one week is too short a window to draw conclusions.

Here's what concerns me as someone who's read the STEP trials closely: most GI side effects emerge or worsen as doses increase. If she started at 0.25 mg (the standard initiation dose), she's at the lowest rung of the ladder. The nausea often hits when people move to 0.5 mg or 1 mg. Framing week one as representative of the full experience could leave her followers unprepared.

What she got genuinely right: adding incidental movement through her Uber delivery work is legitimate physical activity. Research on non-exercise activity thermogenesis (NEAT) by Levine et al., 2006, in Science showed that spontaneous movement like stair climbing and frequent transitions from sitting to standing contributes meaningfully to total daily energy expenditure. She shouldn't dismiss this as "not real" exercise.

• Appetite suppression in week one: consistent with GLP-1 receptor agonist pharmacology.
• "No side effects" as a general statement: premature and potentially misleading for her audience.
• Incidental movement counting: scientifically defensible.

What should you actually know?

If you're watching this video and thinking your own Ozempic experience will look like hers, pump the brakes. GI side effects are the most common reason people discontinue semaglutide early, and they often don't show up in week one at starting doses.

A few things worth knowing before you read too much into a first-week update. First, individual response to semaglutide varies significantly. Genetics, baseline GI motility, and starting dose all affect tolerability. Second, the appetite suppression she describes is a feature, not a bug, but it can also lead to inadequate protein intake if not managed intentionally. Research by Wilding and colleagues emphasized the importance of dietary quality alongside GLP-1 therapy. Third, movement matters even on medication. A 2023 paper by Almandoz et al. in Obesity confirmed that combining GLP-1 therapy with increased physical activity produced better lean mass retention than medication alone. Her instinct to add gym time is sound.

FormBlends recommends discussing any GLP-1 therapy with a licensed clinician before starting, particularly if you have a personal or family history of thyroid tumors, pancreatitis, or severe GI conditions.

Bottom line: Should you take this video at face value?

No, but not because she's being dishonest. She's sharing one week of lived experience from what sounds like a low starting dose. That's a narrow slice of a much longer, more variable process. The appetite suppression she's noticing is pharmacologically real. The "no side effects" headline is statistically lucky, not statistically typical. Watch her channel for month two and three updates before forming any conclusions about how well-tolerated this medication is. That's when the fuller picture usually emerges.